A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the pharmacokinetic profile and safety after biweekly
(every 2-week) intramuscular (IM) injections (6 injections) of risperidone long acting
injectable 25, 37.5, or 50 mg/dose in schizophrenic patients. The efficacy of the study
medication will also be assessed.